Alzamend Neuro Inc

ALZN

Company Profile

  • Business description

    Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

  • Contact

    3480 Peachtree Road NE
    Second Floor Suite 103
    AtlantaGA30326
    USA

    T: +1 844 722-6333

    https://www.alzamend.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 April 2027

    Employees

    7

Stocks News & Analysis

stocks

SpaceX rally continues, expanding sky-high valuations

SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.
stocks

This US AI champion’s stock is too cheap to ignore

Even as competition looks likely to build, the company remains a leading wide-moat business securely at the center of the AI ecosystem.
stocks

Why SpaceX is coming to your Super Fund

Most Australians will end up owning SpaceX — whether they like it or not.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,043.6029.60-0.33%
CAC 408,467.9837.190.44%
DAX 4025,026.8092.130.37%
Dow JONES (US)51,564.7072.150.14%
FTSE 10010,399.70108.91-1.04%
HKSE23,924.81387.35-1.59%
NASDAQ26,517.93496.281.91%
Nikkei 22571,314.67261.180.37%
NZX 50 Index13,443.5880.270.60%
S&P 5007,500.5880.481.08%
S&P/ASX 2008,826.4030.20-0.34%
SSE Composite Index4,090.4817.59-0.43%

Market Movers